EDIT vs MELI · rev $32.3M vs P/E 43, rev $20.78B
Editas Medicine Inc (EDIT) versus MercadoLibre Inc. (MELI) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported MELI revenue for 2024-12-31 was $20.78B. Net income was $1.91B. Revenue was up 387.6% from 2023-12-31 to 2024-12-31. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
EDIT currently screens at market cap $375.2M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Not investment advice. Open the EDIT and MELI stock pages for the full models.
Not investment advice.